Targeted therapy with favorable efficacy and safety profile

Photo of author
Written By Kampretz Bianca

Lorem ipsum dolor sit amet consectetur pulvinar ligula augue quis venenatis. 

Special report|
With friendly support from:
Incyte Biosciences Germany GmbH, Munich

Ruxolitinib Cream for Nonsegmental VitiligoThe

Non-segmental vitiligo is a chronic autoimmune skin disease that requires treatment. Patchy depigmentation on the face and entire body is often associated with a lot of suffering. With ruxolitinib cream, those affected can, for the first time, receive approved topical therapy. If used as directed, the costs are covered by statutory health insuranceB. The selective JAK1 (Janus kinase 1)/JAK2 inhibitor specifically intervenes in the pathomechanism, which can further delay depigmentation and induce repigmentation.

Source link

Leave a Comment

data data data data data data data data data data data data data data data data data data data data data data data data data data data data data data data data data data data data